Mergers & acquisitions
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
Frontage Holdings Corporation announced 11736655 CANADA LTD., an indirectly wholly-owned subsidiary of the Group through Frontage Laboratories, Inc., entered into a share purchase agreement with J&J Corporate Services, Inc., an independent third party.
IBA, the world’s leading provider of solutions for the diagnosis and treatment of cancer, announces that it has sold RadioMed Corporation, IBA’s VISICOIL™ fiducial markers business, to IZI Medical Products LLC, a leading interventional medical device company in a deal that is worth between USD 14 and 16 million to IBA.
The companies had to undergo a number of delays as regulatory agencies from across the globe looked closely at the deal to see if there was a potential the combined companies could create a monopoly in the market and stifle competition.
Following a partnership with Bit Bio announced earlier this month, this morning, CRL announced the acquisition of HemaCare for approximately $380 million in cash.
The Beacon optofluidic technology will be used to speed the identification of lifesaving treatments for deadly viruses including Ebola, Lassa and others.
Merck snapped up the company to gain ArQule’s lead investigational candidate, ARQ 531, a novel, oral Bruton’s tyrosine kinase inhibitor currently in a Phase II dose-expansion study for the treatment of B-cell malignancies.
Sanofi announced it is acquiring Synthorx for $68 per share in cash, a value of $2.5 billion. The deal has been unanimously approved by both companies’ boards.
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
€8 million acquisition brings a wide range of revenue-generating products in orthopaedic, spine, dental and sports surgery
PRESS RELEASES